Recent Advances in the Development of PI3K/mTOR-Based Anticancer Agents: A Mini Review

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Cancer is a global health threat driven by uncontrolled cell growth.
• Deregulation of the mammalian target of rapamycin (mTOR) pathway is a key factor in cancer development.
• Targeting the mTOR pathway with inhibitors is a promising therapeutic strategy.

Purpose of the Study:

• To review and critically discuss the design of novel selective mammalian target of rapamycin (mTOR) inhibitors for cancer treatment.
• To provide comprehensive information on various chemical scaffolds investigated for mTOR inhibition.
• To highlight recent advancements in preclinical and early clinical trials of mTOR inhibitors.

Main Methods:

• Literature review of recent research (last three years) on mTOR inhibitors in cancer.
• Analysis of various chemical scaffolds including furoquinoline, phenyl sulphonylureas, and others.
• Discussion of structure-activity relationships for designing selective mTOR inhibitors.

Main Results:

• Several chemical scaffolds, such as furoquinoline, phenyl sulphonylureas, and thienopyrimidine, show potential for mTOR inhibition.
• Ongoing preclinical and early clinical trials are evaluating the efficacy of various mTOR inhibitors.
• The development of selective inhibitors is crucial for improved cancer therapy.

Conclusions:

• Novel selective mammalian target of rapamycin (mTOR) inhibitors hold significant promise for advanced cancer treatment.
• Continued research into diverse chemical scaffolds is essential for optimizing inhibitor design and efficacy.
• Targeting the mTOR pathway remains a key focus in the development of next-generation cancer therapeutics.